Evidence map›Paper›PMID 37989636›Full record

ReviewInfectious disease clinics of North America2023

Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation.

Kathleen M Doss, Madeleine R Heldman, Ajit P Limaye

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infectious disease clinics of North America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Virus-Specific T-Cell Therapy for Prophylaxis and Treatment of Cytomegalovirus Infections After Transplantation: a Scoping Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kathleen M DossDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Madeleine R HeldmanDivision of Infectious Diseases, Department of Medicine, Duke University, Durham, NC, USA.
Ajit P LimayeDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: limaye@uw.edu.
University of Washington · USDuke University · US

Funding

Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)U01AI163090 · NIAID · UNIVERSITY OF WASHINGTON · PI Don J Diamond, Cynthia E Fisher · 2021 to 2026
$17.4M
NIAID NIH HHS U01 AI163090
6 · The paper itself

Abstract

The authors summarize recent updates in the prevention and management of cytomegalovirus (CMV) in solid organ transplant (SOT) recipients with a focus on CMV seronegative recipients of organs from seropositive donors (CMV D+/R-) who are at highest risk of CMV infection and disease. They discuss advantages of preemptive therapy for CMV disease prevention in CMV D+/R- liver transplant recipients, letermovir for CMV prophylaxis, and updates in the development of monoclonal antibodies and vaccines as immune-based preventative strategies. They review the roles of maribavir and virus-specific T cells for management of resistant or refractory CMV infection in SOT recipients.

Indexed as

Cytomegalovirus (CMV)LetermovirMaribavirMonoclonal antibodiesSolid organ transplantVaccinesVirus-specific T cells (VST)

Identifiers

PMID37989636
PMCPMC11102935
OpenAlexW4388835367

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.